

# PARADIGM BIOPHARMACEUTICALS LIMITED



ASX RELEASE

6<sup>th</sup> January 2021

## PARADIGM BIOPHARMACEUTICALS TO PRESENT AT THE 39<sup>TH</sup> ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

---

**Paradigm Biopharmaceuticals Ltd (ASX: PAR)** is pleased to announce it will be presenting at the upcoming 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference. Public listeners will have an opportunity to listen to the live audio (non-video) version of the session via the link provided below. A replay of the webcast will be available shortly after the conclusion of the presentation and will be available on Paradigm's website following the presentation. Paradigm's management will also be participating in several meetings throughout the conference with pharmaceutical companies and specialist US Biotech and Healthcare funds, where the company will be detailing its Phase 3 clinical program for Zilosul<sup>®</sup> and discussing other exciting indications in the company's clinical pipeline.

### Presentation Details:

**Event:** 39<sup>th</sup> Annual J.P. Morgan Healthcare Conference

**Time: AUS:** Wednesday 13<sup>th</sup> January, 8:20am (AEDT)

**US:** Tuesday 12<sup>th</sup> January, 4:20pm (Eastern)

**Link:** [https://jpmorgan.metameetings.net/events/healthcare21/sessions/35263-paradigm-biopharmaceuticals-ltd/webcast?gpu\\_only=true&kiosk=true](https://jpmorgan.metameetings.net/events/healthcare21/sessions/35263-paradigm-biopharmaceuticals-ltd/webcast?gpu_only=true&kiosk=true)

### About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals LTD (ASX: PAR) is a late-stage drug development company with the mission to develop and commercialise pentosan polysulphate sodium for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection or genetic predisposition.

Authorised for release by Paul Rennie, CEO & Interim Executive Chairman.

To learn more about Paradigm Biopharmaceuticals please visit: [www.paradigmbiopharma.com](http://www.paradigmbiopharma.com)

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

**Paradigm Biopharmaceuticals Ltd**

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: [investorrelations@paradigmbiopharma.com](mailto:investorrelations@paradigmbiopharma.com)